more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

  ()
BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.
Tags: Biotechnology / Pharmaceuticals

BioMarin Advances VOXZOGO Toward Full FDA Approval

  ()
BioMarin submits sNDA for traditional VOXZOGO approval in achondroplasia with a Feb 2027 PDUFA date backed by extensive long-term data and an expanding skeletal dysplasia market opportunity.
Tags: Biotechnology / Pharmaceuticals

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

  ()
Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is selling its Phase 3 antibiotic to Biossil for up to US$104.5 million in milestones, refocusing on its oncology drug ivonescimab.
Tags: Biotechnology / Pharmaceuticals

Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target

  ()
Roth, Chardan Capital, and H.C. Wainwright have all issued "Buy" ratings on Coya Therapeutics Inc. (COYA:NASDAQ) in 2026. Read on to find out why analysts are intrigued.
Tags: Biotechnology / Pharmaceuticals

Houston ALS Biotech Coya Eyes 2028 Approval Path

  ()
Coya Therapeutics advances COYA 302 for ALS with strong analyst support and a key 2027 readout ahead. Discover the catalysts and industry trends driving this Houston biotech.
Tags: Biotechnology / Pharmaceuticals

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Tags: Biotechnology / Pharmaceuticals

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

  ()
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.
Tags: Biotechnology / Pharmaceuticals

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
Tags: Biotechnology / Pharmaceuticals

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Research Report
  ()
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.
Tags: Biotechnology / Pharmaceuticals

Air Force Bases Renew Their Contracts With Cleantech Pioneer

  ()
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

  ()
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?

  ()
Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.
Tags: Biotechnology / Pharmaceuticals

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

  ()
Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.
Tags: Biotechnology / Pharmaceuticals

French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Research Report
  ()
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout.
Tags: Biotechnology / Pharmaceuticals

Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity

  ()
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors.
Tags: Biotechnology / Pharmaceuticals

Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains.
Tags: Biotechnology / Pharmaceuticals

Satellos Bioscience Fast Track Win Fuels DMD Hopes

  ()
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.
Tags: Biotechnology / Pharmaceuticals

Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings

  ()
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial.
Tags: Biotechnology / Pharmaceuticals

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1

  ()
Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

uniQure Epilepsy Gene Therapy Data Draws Investor Focus

  ()
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.
Tags: Biotechnology / Pharmaceuticals

A New Obesity Drug Just Reached Human Trials. Here's What Comes Next

  ()
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application.
Tags: Biotechnology / Pharmaceuticals

San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach

Research Report
  ()
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts.
Tags: Biotechnology / Pharmaceuticals

Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating

  ()
uniQure N.V. (QURE:NASDAQ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction.
Tags: Biotechnology / Pharmaceuticals

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth

  ()
Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.
Tags: Biotechnology / Pharmaceuticals

Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand

  ()
Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 105 Next